At a glance
What is it—and why does it matter?
Vilon is identified as a synthetic peptide bioregulator (a lab-made peptide described as regulating biological processes). Vilon is reported to activate cellular synthetic processes via ribosomal gene reactivation linked to deheterochromatinization of nucleolus organizer regions. In an ex vivo cell culture of lymphocytes from old people, Vilon is reported to cause deheterochromatinization (unrolling) of total heterochromatin.
Sources for this introduction: [1] [2] [3]
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
What is it?
A molecule, not a product name.
Identity
Vilon is identified as a synthetic peptide bioregulator (a lab-made peptide described as regulating biological processes).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The effect of the synthetic peptide bioregulator Vilon on structural and facultative heterochromatin of cultured lymphocytes from old people has been studied.”
Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people. · Abstract
pubmed:15105581:b5362d53e4d9:b5362d53e4d9
How does it work?
Target, response, and disposition.
Mechanism
Vilon is reported to activate cellular synthetic processes via ribosomal gene reactivation linked to deheterochromatinization of nucleolus organizer regions.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“(b) activates synthetic processes caused by the reactivation of ribosomal genes as a result of deheterochromatinization of nucleolus organizer regions;”
Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people. · Abstract
pubmed:15105581:b5362d53e4d9:b5362d53e4d9
Mechanism
An ex vivo spleen organotypic tissue culture model was used to assess vilon and cyclophosphan effects on explant development in rats at two ages (1 day and 2 years).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“There was also studied in spleen organotypic tissue culture the effect of vilon and cyclophosphan on the development of explants of rats of various age: 1 day and 2 years old.”
[Combined effect of vilon and cyclophosphane on tumor transplants and lymphoid tissue explants in mice and rats of various age]. · Abstract
pubmed:14743610:313e4922e1d9:313e4922e1d9
What has been studied?
What the evidence says.
Study findings
In an ex vivo cell culture of lymphocytes from old people, Vilon is reported to cause deheterochromatinization (unrolling) of total heterochromatin.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The data obtained indicate that Vilon (a) induces unrolling (deheterochromatinization) of total heterochromatin;”
Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people. · Abstract
pubmed:15105581:b5362d53e4d9:b5362d53e4d9
Study findings
Vilon is reported not to decondense pericentromeric structural heterochromatin under the studied conditions.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“(d) does not induce decondensation of pericentromeric structural heterochromatin.”
Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people. · Abstract
pubmed:15105581:b5362d53e4d9:b5362d53e4d9
Study findings
Vilon is reported to derepress genes that were silenced due to condensation of euchromatic regions into facultative heterochromatin.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“(c) releases the genes repressed due to the condensation of euchromatic regions forming facultative heterochromatin;”
Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people. · Abstract
pubmed:15105581:b5362d53e4d9:b5362d53e4d9
Risks and interactions
Risks, organized for scanning.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Additional research & classification gaps
2 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.
Inspect contextual research (2)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Synthetic dipeptides are reported to stimulate neutrophil migration (chemotaxis) and phagocytic activity.
Research context only—not evidence of a treatment effect.
- Natural and synthetic thymic peptides as therapeutics for immune dysfunction.
Synthetic dipeptides activated neutrophil chemotaxis and phagocytosis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Vilon is described as a newly synthesized dipeptide with immunomodulatory activity.
Research context only—not evidence of a treatment effect.
- Natural and synthetic thymic peptides as therapeutics for immune dysfunction.
A novel immunomodulatory dipeptide was synthesized and termed Vilon.
Research status + gaps
What still needs better answers?
- No publishable claim yet for: administration, contraindication, interaction, regulatory, safety
- 17 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (12), assurance_score_below_0.72 (3), current_regulatory_source_required (3), extraction_ambiguity (15), high_risk_requires_regulatory_or_two_independent_sources (5), no_direct_support (15)
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- [Combined effect of vilon and cyclophosphane on tumor transplants and lymphoid tissue explants in mice and rats of various age]. ↗
pubmed · published 2003-01-01 · retrieved 2026-09-09T10:53:20Z
- Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people. ↗
pubmed · published 2004-01-01 · retrieved 2026-09-04T22:25:32Z
- Natural and synthetic thymic peptides as therapeutics for immune dysfunction. ↗
pubmed · published 1997-01-01 · retrieved 2026-09-09T23:06:56Z
Publication history and provenance
Version 2 · Automated assessment · 2026-09-09T23:16:14Z
5884ead0960882a62745da7bf9674dd2dbdfe9fd492505c1a6f1b883ef1c2f65